Loading
A telemedicine company's survey of patients it prescribed ivermectin and mebendazole reported that most felt better; the journal attached an expression of concern in June 2026 and retracted the paper in October 2026, citing methodological and analytical problems.
The cohort comprised 197 patients with cancer prescribed compounded ivermectin 25 mg with mebendazole 250 mg off-label through a US telemedicine platform, of whom 122 completed a six-month digital survey; the authors report a self-assessed 'clinical benefit ratio' of 84.4 percent, with 48.4 percent reporting regression or no evidence of disease, 36.1 percent stable and 15.6 percent progression, side effects in 25.4 percent, and 27.9 percent also on chemotherapy (Hulscher cohort 2026). On 9 June 2026 the journal's editorial board issued an expression of concern citing serious concerns about the verifiability, statistical reliability and ethical oversight of the dataset, and opened an audit of the institutional review board documentation, the source records confirming the 197 baseline diagnoses and the medical documentation behind the reported regressions (Anticancer Research expression of concern 2026). The board also stated that it does not endorse or condone unvalidated off-label use of medications for unapproved oncological indications (Anticancer Research expression of concern 2026). In October 2026, after post-publication review, independent expert assessments and the authors' appeal, the editor retracted the article because of methodological and analytical problems (Anticancer Research retraction notice 2026; PubMed 42823188).
This is the paper most often quoted online as proof. Patients reporting how they feel to the company that sold them the treatment, with 38 percent not answering, cannot show whether a cancer shrank, and the journal has since retracted the paper.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Mebendazole, Ivermectin, Misinformation and unproven therapies.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Mebendazole, Ivermectin, Misinformation and unproven therapies.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Mebendazole, Ivermectin, Misinformation and unproven therapies.
Shares Off-label, Ivermectin, Misinformation and unproven therapies.
Shares Off-label, Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
Shares Off-label, Ivermectin, Misinformation and unproven therapies.
Shares Off-label, Fenbendazole, ivermectin and other internet 'repurposed cures', Mebendazole, Ivermectin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/